Eye-movement biomarkers reveal neurodegenerative circuit dysfunction
PrimaryNeuroClues' core causal theory is that neurological and neurodegenerative diseases disrupt brain circuits that control eye movements, and these disruptions produce measurable ocular-motor signatures. By quantifying saccades, fixation stability, smooth pursuit, latency, gaze palsy, and related eye-movement features, the platform should detect disease-linked neurological impairment more objectively than a purely qualitative clinical exam. Testable predictions are that patients with Parkinson's disease, Alzheimer's disease, atypical parkinsonism, multiple sclerosis, concussion-related impairment, or related disorders will show reproducible eye-movement abnormalities; that specific disorders will show distinguishable ocular-motor patterns; and that these measures will correlate with clinical diagnosis, disease subtype, or neurological functional status.
Popperian evaluation
The starting premise is strong: eye movements depend on distributed brain circuits, and several neurological diseases disturb those circuits in ways that can be measured. The theory does not require a speculative new biology. It rests on known clinical signs, including saccadic latency changes in Alzheimer's disease, saccadic hypometria in Parkinson's disease, and vertical gaze palsy in progressive supranuclear palsy. The weak point is measurement specificity. Aging, medication, fatigue, attention, ocular disease, and comorbidities can all move the signal around.
Supporting evidence: A 2024 review reports ocular motor disturbances across Alzheimer's disease, Parkinson's disease, atypical parkinsonism, and related neurodegenerative disorders.; Alzheimer's disease and related disorders are linked with increased saccadic latencies and fixation instability.; Parkinson's disease is linked with saccadic hypometria and mild smooth-pursuit impairment.; Progressive supranuclear palsy and corticobasal syndrome show more distinct ocular-motor signs, including vertical supranuclear gaze palsy and saccadic apraxia.
Counter evidence: The evidence context itself flags a key assumption: eye tracking must separate disease signal from normal variation, measurement noise, medication effects, aging, and comorbidities.; Some abnormalities may be shared across disorders, which can weaken disease-level specificity.
The theory explains a real cluster of observations: different diseases affect eye-movement control in partly different ways, and those changes can map onto diagnosis, subtype, gait status, or functional state. That is a useful explanatory frame. It does not yet prove that ocular-motor signatures beat alternative explanations such as general cognitive slowing, attention problems, medication effects, visual impairment, or nonspecific motor dysfunction. The strongest version would need disorder-separated validation, not just abnormal versus normal eye movement.
Supporting evidence: The 2024 review links Alzheimer's disease with increased saccadic latency and fixation instability, Parkinson's disease with saccadic hypometria, and atypical parkinsonism with distinct gaze and saccade abnormalities.; A 2021 Parkinson's disease study links antisaccade abnormalities with freezing of gait and gait/gaze network connectivity.; The SCA2 and SCA7 longitudinal study used oculomotor recordings alongside clinical, gait, imaging, fluid, and retinal measures.
Counter evidence: The theory must still show that measured eye-movement patterns distinguish specific disorders rather than detecting broad neurological impairment.; The SCA study included 15 SCA2 carriers, 15 SCA7 carriers, and 10 controls, so it supports plausibility more than broad diagnostic separation.; The supplied evidence includes reviews and associative studies, not a head-to-head diagnostic trial against expert clinical assessment.
This theory is testable in a clean Popperian sense. It predicts reproducible abnormalities in named disorders, separable ocular-motor patterns across disorders, and correlations with diagnosis, subtype, gait status, disease stage, or functional status. Those claims can fail. If blinded cohorts show no reproducible signal, no subtype separation, or correlations too weak for clinical use, the platform thesis takes a direct hit.
Supporting evidence: The theory names measurable features: saccades, fixation stability, smooth pursuit, latency, gaze palsy, and related eye-movement measures.; It predicts abnormalities in Parkinson's disease, Alzheimer's disease, atypical parkinsonism, multiple sclerosis, concussion-related impairment, spinocerebellar ataxia, and related disorders.; It predicts that specific disorders will show distinguishable ocular-motor patterns rather than one nonspecific abnormal profile.; It predicts correlations with clinical diagnosis, subtype, gait status, disease stage, or neurological functional status.
Counter evidence: Some predictions are broad unless the study predefines thresholds, endpoints, and disorder-specific classification targets.; A weak correlation with clinical status could be interpreted generously unless minimum effect sizes and validation cohorts are fixed before testing.
Reasoning tree
Public endorsements
The evidence shows Antoine Pouppez is NeuroClues' CEO and co-founder, and it shows the company publicly advances an eye-movement biomarker thesis. It does not show Pouppez himself publicly stating, endorsing, or disputing the specific causal theory about neurodegenerative circuit dysfunction and measurable ocular-motor signatures. On this record, he stays silent.
Evidence publication IDs: 9eec68f9-a1fe-452c-ae96-43d717fbf3a0, 27e63f38-0987-4203-918e-970ea8a58f41
Antoine Pouppez is identified in the evidence as NeuroClues' CEO and co-founder, and the public records tied to him describe the company as using high-speed eye tracking and objective eye-movement biomarkers to improve neurological diagnosis. The TechCrunch record explains how the device works in the clinic, and the Sud Ouest record says the startup promises objective biomarkers from a ten-minute eye-movement exam. That is support for the core theory, not silence or contradiction.
Evidence publication IDs: 27e63f38-0987-4203-918e-970ea8a58f41, 647e074f-8ea8-4bb4-9c0c-be08da30c1cb, 9eec68f9-a1fe-452c-ae96-43d717fbf3a0
Bertrand Gaymard publicly endorses the theory on NeuroClues' website. In Wayback snapshots from 2023-02-01 and 2024-02-23, he is quoted in testimonials saying neuroClues brings or will bring decades of scientific eye-tracking evidence to neurologists and helps quantify the neurological examination. That is a direct public endorsement of the company's claim that eye-movement measurement can objectively detect neurological dysfunction.
The evidence places Pierre Daye as a founder of neuroClues, but it does not show him publicly stating that eye-movement measures reveal neurodegenerative circuit dysfunction or that ocular-motor signatures can diagnose disease. The only direct quote attributed to him here is about Lance M. Optican as a mentor, which is unrelated to the company theory.